ArticleDrug design, development and therapy2025
Liu Wei Di Huang Decoction Alleviates Renal Fibrosis by Inhibiting Endothelial Mesenchymal Transitions via Upregulating Sirt1 Expression and Inhibiting the Wnt/β-Catenin Signaling Pathway.
Article in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A review of the sirtuins family: pivotal regulators and emerging therapeutic targets in renal fibrosis.Renal failure · 2026Review
- Liuweidihuang Pill Attenuates Early Bleomycin-Induced Pulmonary Fibrosis in Mice and Is Associated with Gut Microbiome.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Renal fibrosis (RF) is the final outcome of chronic kidney disease (CKD), which can be triggered by various factors. Liuwei Dihuang Decoction (LWDHD) has been clinically established as an effective treatment for CKD, demonstrating anti-inflammatory, antioxidant, and antifibrotic effects. However, the specific molecular mechanisms underlying the therapeutic effectiveness of LWDHD remain unknown. Aim: Prediction of key active ingredients, targets, and mechanistic pathways of LWDHD in RF treatment. Materials and Methods: The bioactive components of LWDHD were identified and quantified using ultra-performance liquid chromatography-tandem quadrupole mass spectrometry (UHPLC-MS/MS). A network pharmacology approach was employed to predict the key targets of these bioactive components. A rat model of renal tubulointerstitial fibrosis was created through unilateral ureteral obstruction (UUO). Rats were divided into six groups: sham operation, UUO, low-dose LWDHD (LW-L), medium-dose LWDHD (LW-M), high-dose LWDHD (LW-H), and enalapril group. Continuous gavage of treatments was administered for 2 weeks. The renal tissues were histopathologically assessed, including HE, Masson's trichrome, and Sirius red staining, immunohistochemistry, co-staining and Western blot analysis to evaluate the effects of LWDHD on renal fibrosis. Transforming growth factor beta-1 (TGF-β1) was employed to stimulate endothelial-mesenchymal transition (EndMT) in EA.hy926 cells. The inhibitory effect of LWDHD on EndMT was validated through cellular morphology observations, Western blotting, and immunofluorescence assays. Results: LWDHD showed promise as a therapeutic agent by alleviating renal pathological injury and lowering collagen fiber accumulation. It enhanced Sirt1 expression while inhibiting the Wnt/β-catenin signaling pathway. Moreover, LWDHD increased the levels of the endothelial marker CD31 and decreased the expression of fibrosis-associated proteins, such as α-smooth muscle actin (α-SMA) and vimentin, thereby mitigating renal fibrosis. Conclusion: LWDHD has the potential to alleviate renal fibrosis, possibly through the upregulation of Sirt1, which inhibits the Wnt/β-catenin signaling pathway and thereby reduces EndMT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.